Gil Yosipovitch, MD: Next Steps Following FDA Approval of Nemolizumab for Prurigo Nodularis скачать в хорошем качестве

Gil Yosipovitch, MD: Next Steps Following FDA Approval of Nemolizumab for Prurigo Nodularis

After the August 13 announcement of the US Food and Drug Administration (FDA) approval of nemolizumab (Nemluvio) for adults with prurigo nodularis (PN), the HCPLive team interviewed an investigator from the OLYMPIA trial system. Gil Yosipovitch, MD, professor of dermatology for the Miller School of Medicine at the University of Miami, spoke about significance of the approval for patients with prurigo nodularis, a neuroimmune skin disease. In this interview, he was asked to describe any challenges or unexpected outcomes encountered during the OLYMPIA trials, as well as the future of PN treatment. Check out our summary here: https://www.hcplive.com/view/gil-yosi... #PrurigoNodularis #dermatology